Suppr超能文献

在犬体内,一种黑皮质素-4 拮抗剂多肽 TCMCB07 的药代动力学和安全性。

Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs.

机构信息

Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA.

TCI Peptide Therapeutics, Columbia, MO, USA.

出版信息

Pharmacol Res Perspect. 2021 May;9(3):e00777. doi: 10.1002/prp2.777.

Abstract

The melanocortin-4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high- (2.25 mg kg ) (n = 5) and low-dose TCMCB07 (0.75 mg kg ) (n = 5) once daily for 28 days with a 14-day washout period between groups. Histamine levels, complete blood count, chemistry panel, blood pressure, 24-hour Holter recording, and pharmacokinetic parameters were monitored in the high-dose group. Physical examination changes were limited to weight gain and darkening of the coat color. There was no elevation of plasma histamine within 24 hours of injection but there was a significant elevation of plasma histamine across time. An approximately doubled eosinophil count and an approximately 25% increase, and then 25% decrease back to pre-treatment plasma phosphorous were also found, although both remained within the reference interval. Serial blood pressure and 24-hour Holter monitors revealed no clinically relevant changes. A difference was found in the AUC between dosing groups and a significant effect of dose, time, and interaction was noted for V . Low-dose TCMCB07 had a C of 2.1 ug ml at day 28, compared to high-dose TCMCB07 which had a C 3.6 ug ml at day 28. Once-daily subcutaneous administration of TCMCB07 was well-tolerated for up to 28 days in dogs when administered at doses one and three times (0.75 mg kg and 2.25 mg kg ) the predicted therapeutic dose and pharmacokinetic parameters are described. SIGNIFICANCE STATEMENT: Melanocortin-4 receptor (MC4R) antagonistic peptide TCMCB07 is safe at both low and high doses in dogs. Therapy was tolerated well as determined by physical examination, clinical pathology, and cardiovascular parameters; darkening of the coat was noted with treatment and resolved with discontinuation. Pharmacokinetics are described and further study in the naturally occurring canine model is warranted.

摘要

黑素皮质素 4 受体 (MC4R) 拮抗剂 TCMCB07 被开发用于治疗恶病质。本研究的目的是研究 TCMCB07 皮下给药给健康犬的药代动力学和安全性。犬接受高剂量 (2.25 mg/kg) (n=5) 和低剂量 TCMCB07 (0.75 mg/kg) (n=5) 治疗,每天一次,两组之间有 14 天的洗脱期。高剂量组监测组胺水平、全血细胞计数、化学面板、血压、24 小时 Holter 记录和药代动力学参数。体检变化仅限于体重增加和毛色变暗。注射后 24 小时内血浆组胺没有升高,但随着时间的推移,血浆组胺显著升高。还发现嗜酸性粒细胞计数增加约一倍,磷升高约 25%,然后降至治疗前水平的 25%,但两者均在参考区间内。连续血压和 24 小时 Holter 监测未发现临床相关变化。发现剂量组之间 AUC 存在差异,并且剂量、时间和相互作用对 V 有显著影响。低剂量 TCMCB07 在第 28 天的 C 为 2.1 ug/ml,而高剂量 TCMCB07 在第 28 天的 C 为 3.6 ug/ml。在犬中,每天一次皮下给予 TCMCB07,剂量为预测治疗剂量的 1 倍和 3 倍 (0.75 mg/kg 和 2.25 mg/kg),耐受性良好,持续 28 天,描述了药代动力学参数。意义:黑素皮质素 4 受体 (MC4R) 拮抗剂 TCMCB07 在犬中低剂量和高剂量均安全。通过体检、临床病理学和心血管参数确定治疗耐受性良好;治疗后毛色变暗,停药后恢复。描述了药代动力学,并在自然发生的犬模型中进一步研究是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d1/8135083/30b592260cca/PRP2-9-e00777-g006.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验